Brief: Sorrento Successfully Completes Phase 1 Study And Is Proceeding To Implement Global Registrational Trials With Sti-1558

Sorrento Therapeutics

17/10/2022 14:14

Oct 17 (Reuters) - Sorrento Therapeutics Inc  SRNE.O :
    * SORRENTO SUCCESSFULLY COMPLETES PHASE 1 STUDY AND IS
PROCEEDING
TO IMPLEMENT GLOBAL REGISTRATIONAL TRIALS WITH STI-1558, AN ORAL
MPRO INHIBITOR AS A STANDALONE ORAL TREATMENT AND PREVENTION OF
COVID-19 WITHOUT THE NEED FOR A RITONAVIR BOOSTER
    * SORRENTO THERAPEUTICS INC- THERE WERE NO SERIOUS ADVERSE
EVENTS
(SAES) OR SEVERE TREATMENT EMERGENT ADVERSE EVENTS
    * SORRENTO THERAPEUTICS INC- NO DOSE LIMITING TOXICITIES
WERE
NOTED AND THERE WERE NO PREMATURE TERMINATIONS FROM STUDY
POST-TREATMENT

Source text for Eikon:  ID:nGNX5jhnqX 
Further company coverage:  SRNE.O 
 ((Reuters.Briefs@thomsonreuters.com;))